NovAccess Global Inc.(XSNX.US)

FACTBOX-How four US childhood vaccine recommendations have changed

The Trump administration has revised childhood vaccine recommendations, shifting from universal vaccination to shared decision-making between parents and healthcare providers for influenza, rotavirus, meningococcal disease, and hepatitis A. Major medical organizations oppose these changes, warning of increased infections and hospitalizations. The CDC's new guidelines reflect a lack of consensus on universal vaccination and aim to align with practices in other wealthy countries. Despite the changes, leading health authorities continue to advocate for these vaccines to protect public health.

FOCUS-Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality

U.S. Health Secretary Robert F. Kennedy Jr.'s anti-vaccine policies are causing frustration among vaccine makers, leading to decreased vaccination rates and valuation pressures for biotech firms. The administration's changes, including the end of broad vaccine recommendations, have raised concerns about public health and investor confidence. Major companies like Pfizer and Sanofi have publicly criticized Kennedy's rhetoric, which they believe undermines scientific merit. While long-term prospects for vaccines remain strong, political influences are complicating the investment landscape for smaller biotech firms.

23:17 ET Inaugural Cures Conference to be held on Thursday, February 5, 2026 in NYC

The inaugural Cures Conference will take place on February 5, 2026, in New York City, bringing together scientists, physicians, and industry leaders to discuss innovations in healthcare. Key topics include the role of artificial intelligence in accelerating innovation and improving global health outcomes. Notable panelists include Jack Hidary, Dr. Edward Neilan, and Dr. Shoshana Shendelman, among others. The event aims to leverage collective expertise to advance treatment development and real-world implementation.

The Nasdaq Biotechnology Index rose over 2.4%, outperforming the broader U.S. stock market. Novavax increased by 20.67%, while Ironwood Pharma, Moderna, Vir Biotechnology, BioNTech, Annexon, and Aura Biosciences saw gains between 15.94% and 10.26%. Solid Biosciences rose by 9.61%. In contrast, Zenas Biopharma fell by 6.18%, PepGen dropped by 9.08%, and Legend Biotech decreased by 11.40%

Researchers at FIU are developing personalized cancer treatment, showing promise for hard-to-treat diseases, aided by philanthropic investment.

In Miami on January 21, 2026, researchers at Florida International University (FIU) are making strides in tailoring cancer treatment to individual patients, demonstrating encouraging outcomes for individuals with difficult-to-treat cancers. This innovative approach is bolstered by recent philanthropic funding, which is facilitating the expansion of research in this area. The personalized cancer treatment has yielded promising results for patients, marking a significant advancement in the field.